Visco-supplement compositions derived from a transcellular fluid, such as human amniotic fluid, human aqueous humor fluid, or human vitreous fluid are described. Also described are methods for treating inflammatory conditions of the musculoskeletal system, such as joint inflammation, and methods of lubricating a joint using the described visco-supplement compositions.

Visco-supplement compositions derived from a transcellular fluid, such as human amniotic fluid, human aqueous humor fluid, or human vitreous fluid are described. Also described are methods for treating inflammatory conditions of the musculoskeletal system, such as joint inflammation, and methods of lubricating a joint using the described visco-supplement compositions.

The invention relates to methods of modifying DNA methylation by contacting a cell with a catalytically inactive site specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences.

The invention relates to methods of modifying DNA methylation by contacting a cell with a catalytically inactive site specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences.

Methods of determining the suitability of a subject for treatment with a therapeutic agent are provided. Methods of providing a personalized treatment protocol based on suitability of a subject to be treated with a therapeutic agent are also provided, as are methods of treating those subjects who are suitable.

Methods of determining the suitability of a subject for treatment with a therapeutic agent are provided. Methods of providing a personalized treatment protocol based on suitability of a subject to be treated with a therapeutic agent are also provided, as are methods of treating those subjects who are suitable.

The present disclosure provides modified induced pluripotent stem cell (iPSC) derived microglia comprising a microglia targeting and activation protein, a microglia regulatory protein, an interfering RNA sequence, a microRNA effector, a non-coding RNA effector, at least one transgene encoding the aforementioned, or a combination thereof. Also provided are methods for treating cancer (e.g., brain cancers) and sensitizing cancer cells to phagocytosis and other cell death pathways with the modified induced pluripotent stem cell (iPSC) derived microglia.

The present disclosure provides modified induced pluripotent stem cell (iPSC) derived microglia comprising a microglia targeting and activation protein, a microglia regulatory protein, an interfering RNA sequence, a microRNA effector, a non-coding RNA effector, at least one transgene encoding the aforementioned, or a combination thereof. Also provided are methods for treating cancer (e.g., brain cancers) and sensitizing cancer cells to phagocytosis and other cell death pathways with the modified induced pluripotent stem cell (iPSC) derived microglia.

Systems, devices, and methods for treating a nerve injury in a patient are provided. The system includes an extracellular matrix, a neutralizing element, and a reconstituting element. The extracellular matrix is configured to promote and/or sustain the growth of tissue and/or associated tissue properties proximate the nerve injury.

Systems, devices, and methods for treating a nerve injury in a patient are provided. The system includes an extracellular matrix, a neutralizing element, and a reconstituting element. The extracellular matrix is configured to promote and/or sustain the growth of tissue and/or associated tissue properties proximate the nerve injury.